Your shopping cart is currently empty

SN50 acetate is a cell permeable inhibitor of NF-κB translocation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | In Stock | In Stock | |
| 5 mg | $196 | In Stock | In Stock | |
| 10 mg | $295 | In Stock | In Stock | |
| 25 mg | $472 | In Stock | In Stock | |
| 50 mg | $672 | In Stock | In Stock | |
| 100 mg | $893 | In Stock | In Stock | |
| 200 mg | $1,180 | - | In Stock |
| Description | SN50 acetate is a cell permeable inhibitor of NF-κB translocation. |
| In vitro | Pretreatment with SN50 acetate results in a significant reduction in amount of PI-positive cells at 12, 24, and 48 h time-point post TBI compared with vehicle-treated groups[1]. Topical SN50 acetate suppresses nuclear factor-κB activation in local cells and reduces the incidence of epithelial defects/ulceration in healing corneas. Myofibroblast generation, macrophage invasion, activity of matrix metalloproteinases, basement membrane destruction, and expression of cytokines are all decreased in treated corneas compared with controls[2]. Treating the human gastric cancer cells SGC7901 with SN50 acetate could significantly enhance the effects of LY294002 on inducing cell death after 24 h[3]. SN50 can inhibit translocation of NF-kB and production of inflammatory cytokines that are implicated in lipopolysaccharide (LPS)-induced lung injury[4]. |
| In vivo | Treatment with SN50 acetate accelerates the recovery of motor functional outcome from 1st to 4th day. Animals subjected to SN50 acetate pretreatment demonstrate a significant decrease in the visuospatial learning latencies relative to the control group at 7 and 8 days post-TBI. Pretreatment with SN50 acetate results in a significant reduction of NF-κB p65 protein levels from 6 to 48 h post-TBI and TNF-a protein levels from 12 to 48 h post-TBI[1]. |
| Molecular Weight | 2841.55 |
| Formula | C131H234N36O31S |
| Smiles | O=C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N1[C@@H](CCC1)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N2[C@@H](CCC2)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N3[C@@H](CCC3)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C)N.CC(O)=O |
| Relative Density. | no data available |
| Sequence | Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro |
| Sequence Short | AAVALLPAVLLALLAPVQRKRQKLMP |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | H2O: 10 mM, Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
H2O
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.